MBP8298 enters phase III

Post Reply

1 post • Page 1 of 1

finn: Contributing Author; Posts: 289; Joined: Wed Mar 17, 2004 3:00 pm; Location: Finland; Contact:
Contact finn

Website

MBP8298 enters phase III

Quote

Post by finn » Tue Jun 15, 2004 11:55 am

Sorry, time to leave the board.

-finn

Post Reply

1 post • Page 1 of 1

Similar Topics

Replies

Views

Last post

Ublituximab Phase II Success

Last post by zen2010 « Fri Mar 08, 2019 1:17 am
Posted in Drug Pipeline
Replies: 2
by NHE » Thu Mar 07, 2019 5:10 pm » in Drug Pipeline

First post

Ublituximab targets CD20 and depletes B cells. Researchers report that their phase II study was successful.

Last post

Thks for the info.

It looks like Rituxan or Ocrevus (Anti- CD20 antibodies).
It's for both RR and PP.

2 Replies

1127 Views

Last post by zen2010
Fri Mar 08, 2019 1:17 am
Biomarker for the progressive phase

Last post by frodo « Tue Aug 11, 2020 2:06 am
Posted in MS Etiology and Pathogenesis

by frodo » Tue Aug 11, 2020 2:06 am » in MS Etiology and Pathogenesis

Distinctive sphingolipid patterns in chronic multiple sclerosis lesions

Abstract

Multiple sclerosis (MS) is a CNS disease characterized by...

0 Replies

128 Views

Last post by frodo
Tue Aug 11, 2020 2:06 am
Ozanimod RADIANCE Phase III Trial

Last post by NHE « Sat Apr 25, 2020 4:42 am
Posted in Zeposia (Ozanimod)

by NHE » Sat Apr 25, 2020 4:42 am » in Zeposia (Ozanimod)

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3...

0 Replies

126 Views

Last post by NHE
Sat Apr 25, 2020 4:42 am
Diroximel fumarate phase III study

Last post by NHE « Wed Jul 01, 2020 6:18 am
Posted in Vumerity (diroximel fumarate)

by NHE » Wed Jul 01, 2020 6:18 am » in Vumerity (diroximel fumarate)

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared With Dimethyl Fumarate in Patients With...

0 Replies

183 Views

Last post by NHE
Wed Jul 01, 2020 6:18 am
Ozanimod SUNBEAM Phase III Trial

Last post by NHE « Sat Apr 25, 2020 4:51 am
Posted in Zeposia (Ozanimod)

by NHE » Sat Apr 25, 2020 4:51 am » in Zeposia (Ozanimod)

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month,...

0 Replies

126 Views

Last post by NHE
Sat Apr 25, 2020 4:51 am
from MSUK: Temelimab passes phase IIb

Last post by frodo « Mon Apr 22, 2019 10:23 am
Posted in Drug Pipeline

by frodo » Mon Apr 22, 2019 10:23 am » in Drug Pipeline

Temelimab is the only drug under research that targets a viral protein, and probably the only one that targets the underlying cause of MS....

0 Replies

975 Views

Last post by frodo
Mon Apr 22, 2019 10:23 am
Safety and efficacy of ozanimod in phase II extension

Last post by NHE « Sun May 03, 2020 3:29 am
Posted in Zeposia (Ozanimod)

by NHE » Sun May 03, 2020 3:29 am » in Zeposia (Ozanimod)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Mult Scler. 2019 Aug;25(9):1255-1262....

0 Replies

111 Views

Last post by NHE
Sun May 03, 2020 3:29 am
Ofatumumab Phase IIb Trial, MIRROR Study

Last post by NHE « Sat Aug 22, 2020 4:05 am
Posted in Kesimpta (Ofatumumab)

by NHE » Sat Aug 22, 2020 4:05 am » in Kesimpta (Ofatumumab)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
Neurology. 2018 May 15;90(20):e1805-e1814....

0 Replies

51 Views

Last post by NHE
Sat Aug 22, 2020 4:05 am
Ofatumumab vs. Teriflunomide in Multiple Sclerosis, Phase III Trials

Last post by NHE « Sat Aug 22, 2020 4:18 am
Posted in Kesimpta (Ofatumumab)

by NHE » Sat Aug 22, 2020 4:18 am » in Kesimpta (Ofatumumab)

Ofatumumab versus Teriflunomide in Multiple Sclerosis
N Engl J Med. 2020 Aug 6;383(6):546-557.

Background: Ofatumumab, a subcutaneous anti-CD20...

0 Replies

78 Views

Last post by NHE
Sat Aug 22, 2020 4:18 am

Return to “Drug Pipeline”